Peregrine Completes Patient Enrollment in Randomized Phase II Trial for Bavituximab in Front-Line Non-Small Cell Lung Cancer

Peregrine to Report First Quarter Fiscal Year 2012 Financial Results Before Market on September 9, 2011

Peregrine Prices $7 Million Registered Direct Offering of Common Stock

Peregrine to Present at Stifel Nicolaus Healthcare Conference September 8, 2011 at 11:30 AM EDT

Peregrine Reports Promising 20.7 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial

Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Recent Developments

Peregrine to Report Fourth Quarter and Fiscal Year 2011 Financial Results After Market Close on July 14, 2011

Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung Cancer

Peregrine Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara at ASCO Annual Meeting

Peregrine Appoints Jeffrey Masten as Vice President, Quality as Company Advances Phase II Clinical Programs